CD19 and precursor B-cell acute lymphoblastic leukemia: In a similar way, the EV signature during induction therapy demonstrated that, on D0, a greater proportion of B-ALL patients exhibited high production of EV-CD10+ and EV-CD19+, in contrast to on D35 (Figure 5).